Efficacy and Safety of Rivaroxaban Versus Warfarin in P
With Nonvalvular Atrial Fibrillation: A Subgroup Analys

Thrombosis Research

156, 184-190

DOI: 10.1016/j.thromres.2017.04.010

Citation Report

#	Article	IF	Citations
1	Present Status and Future Orientation of Rivaroxaban Application in Patients With Nonvulvular Atrial Fibrillation. Thrombosis Research, 2017, 156, 191-192.	2.9	0
2	XANAP: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia. Journal of Arrhythmia, 2018, 34, 418-427.	2.0	25
3	Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology, 2018, 72, 141-153.	12.0	61
4	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. American Journal of Therapeutics, 2019, 26, e679.	1.1	4
5	Outcome Reporting From Clinical Trials of Non-Valvular Atrial Fibrillation Treated With Traditional Chinese Medicine or Western Medicine: A Systematic Review. BMJ Open, 2019, 9, e028803.	2.7	9
6	Real-World Investigation on Discontinuation of Oral Anticoagulation After Paroxysmal Atrial Fibrillation Catheter Ablation in China. Annals of Palliative Medicine, 2020, 9, 94046-94946.	1.8	13
7	Cost-Effectiveness Analysis of Dabigatran, Rivaroxaban and Warfarin in the Prevention of Stroke in Patients With Atrial Fibrillation in China. BMC Health Services Research, 2021, 21, 1-10.	3.8	18
8	Evaluation of the “Safe Multidisciplinary App-Assisted Remote Patient-Self-Testing (SMART) Model” for Warfarin Home Management During the COVID-19 Pandemic: Study Protocol of a Multi-Center Randomized Controlled Trial. BMC Health Services Research, 2021, 21, 1-10.	3.8	6
9	The Risk of Gastrointestinal Bleeding Between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 137.	4.2	7
10	Cost-Effectiveness of Anticoagulants for Preventing Stroke in Patients With Non-Valvular Atrial Fibrillation in Mainland China. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 523-530.	1.0	16
11	Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events. Journal of Cardiovascular Pharmacology, 2022, 80, 869.	2.5	4
12	Safety Issues of Herb-Warfarin Interactions. Current Drug Metabolism, 2024, 25, 13-27.	2.5	10
13	Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl ≥ 50 mL/Min: A Retrospective Cohort Study. Cardiovascular Therapeutics, 2025, 2025, 7021330.	3.0	1
14	Evaluation of a Pharmacist-Led Patient-Self-Testing Model for Warfarin Management in Patients Undergoing Mechanical Heart Valve Replacement in China: A Multicentre, Open-Label, Randomised, Controlled Trial. BMJ Open, 2026, 16, e105575.	2.7	1
15	Outcomes of Early Versus Later Anticoagulation in Asian Atrial Fibrillation–Related Stroke: ELAN Subgroup Analysis. Journal of Stroke, 2026, 28, 293-302.	7.6	0